Brief: HLS Therapeutics Announces Q4 2020 Financial Results
18/03/2021 10:35
March 18 (Reuters) - HLS Therapeutics Inc HLS.TO :
* Q4 2020 REVENUE WAS $16.5 MILLION VERSUS $13.9 MILLION IN
Q4
2019
* QTRLY NET LOSS PER SHARE $0.23
* Q4 REVENUE VIEW $16.2 MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nCNWZbtJla
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease